#METABOLOMICS WORKBENCH sdasari_20140930_9217761_mwtab.txt DATATRACK_ID:163 STUDY_ID:ST000115 ANALYSIS_ID:AN000196 PROJECT_ID:PR000104 VERSION 1 CREATED_ON 2016-09-17 #PROJECT PR:PROJECT_TITLE Impact of insulin deprivation and treatment on sphingolipid distribution in PR:PROJECT_TITLE muscle subcellular compartments of streptozotocin-diabetic C57Bl/6 mice. PR:PROJECT_TYPE Targeted metabolomics PR:PROJECT_SUMMARY Insulin deprivation in type 1 diabetes (T1D) individuals increases lipolysis PR:PROJECT_SUMMARY plasma free fatty acids (FFA) concentration, which can stimulate synthesis of PR:PROJECT_SUMMARY bioactive lipids such as ceramides (Cer) and long-chain fatty acid-CoAs PR:PROJECT_SUMMARY Ceramide was shown to decrease muscle insulin sensitivity, and at mitochondrial PR:PROJECT_SUMMARY it stimulates reactive oxygen species production. Here, we show that insulin PR:PROJECT_SUMMARY in streptozotocin diabetic C57BL/6 mice increases quadriceps muscle Cer PR:PROJECT_SUMMARY which was correlated with a concomitant decrease in the body fat and increased PR:PROJECT_SUMMARY FFA, glycosylated hemoglobin level (%Hb A1c), and muscular LCFa-CoA content. PR:PROJECT_SUMMARY alternations were accompanied by an increase in protein expression in LCFa-CoA PR:PROJECT_SUMMARY Cer synthesis (FATP1/ACSVL5, CerS1, CerS5), a decrease in the expression of PR:PROJECT_SUMMARY implicated in muscle insulin sensitivity (GLUT4, GYS1), and inhibition of PR:PROJECT_SUMMARY signaling cascade by Akt? and GYS3? phosphorylation under acute insulin PR:PROJECT_SUMMARY Both the content and composition of sarcoplasmic fraction sphingolipids were PR:PROJECT_SUMMARY affected by insulin deprivation, whereas mitochondrial fraction sphingolipids PR:PROJECT_SUMMARY stable. The observed effects of insulin deprivation were reversed, except for PR:PROJECT_SUMMARY and composition of LCFa-CoA, CerS protein expression, GYS1 gene expression, and PR:PROJECT_SUMMARY status of Akt and GYS3? when exogenous insulin was provided by subcutaneous PR:PROJECT_SUMMARY implants. Principal component analysis and Pearson's correlation analysis PR:PROJECT_SUMMARY close relationships between the features of the diabetic phenotype, the content PR:PROJECT_SUMMARY LCFa-CoAs and Cers containing C18-fatty acids in sarcoplasm, but not in PR:PROJECT_SUMMARY Insulin replacement did not completely rescue the phenotype, especially PR:PROJECT_SUMMARY the content of LCFa-CoA, or proteins implicated in Cer synthesis and muscle PR:PROJECT_SUMMARY sensitivity. These persistent changes might contribute to muscle insulin PR:PROJECT_SUMMARY observed in T1D individuals. PR:INSTITUTE Mayo Clinic PR:DEPARTMENT Endocrinology PR:LABORATORY Dr. Sreekumaran Nair's lab PR:LAST_NAME Nair PR:FIRST_NAME Sreekumaran PR:ADDRESS - PR:EMAIL Dasari.Surendra@mayo.edu PR:PHONE - PR:FUNDING_SOURCE R01-DK-41973, UL1 TR000135, the David Murdock Dole Professorship (K. S. Nair), PR:FUNDING_SOURCE the Stephenson Fellowship (P. Zabielski). PR:PROJECT_COMMENTS 24368672 #STUDY ST:STUDY_TITLE Impact of insulin deprivation and treatment on sphingolipid distribution in ST:STUDY_TITLE muscle subcellular compartments of streptozotocin-diabetic C57Bl/6 mice ST:STUDY_TYPE Insulin depravation ST:STUDY_SUMMARY Experiments were conducted using 13-wk-old male C57BL/6J mice (Jackson ST:STUDY_SUMMARY Bar Harbor, ME). Mice were housed individually with free access to water and ST:STUDY_SUMMARY (TD.10112; Harlan Laboratories, Indianapolis, IN), with a 12:12-h light-dark ST:STUDY_SUMMARY and temperature and humidity control. Mice were acclimated for 1 wk prior to ST:STUDY_SUMMARY beginning of the experiment. The protocol was approved by the Mayo Clinic ST:STUDY_SUMMARY Animal Care and Use Committee. Following a 6-h fast, mice were given ST:STUDY_SUMMARY injections of STZ (125 mg/kg; in sodium acetate buffer, pH = 4.5) (67). ST:STUDY_SUMMARY were repeated on the following day. Control animals received intraperitoneal ST:STUDY_SUMMARY of vehicle. Only mice that displayed blood glucose ?300 mg/dl and an increase ST:STUDY_SUMMARY blood ketones (both values by Precision Xtra glucometer; Abbott Laboratories, ST:STUDY_SUMMARY Park, IL), hyperphagia, and polyuria and were positive for urine glucose ST:STUDY_SUMMARY via dipstick (Uristix, Bayer, Pittsburgh, PA) on day 7 after the first STZ dose ST:STUDY_SUMMARY included in the experiment. Animals that were positive for STZ diabetes ST:STUDY_SUMMARY LinBit subcutaneous insulin implant (LinShin Canada, Toronto, ON, Canada) (79) ST:STUDY_SUMMARY pentobarbital sodium anesthesia (Nebutal, 40 mg/kg of body wt) according to the ST:STUDY_SUMMARY protocol. Each animal received two subcutaneous implants (total dose: 0.2 U/24 ST:STUDY_SUMMARY for >30 days, 10 U/kg for 20-g mice). Insulin treatment was continued for 3 wk. ST:STUDY_SUMMARY animals (C; n = 13) received blank implants. Diabetic control was confirmed by ST:STUDY_SUMMARY measurements of blood and urinary glucose. In some cases, when urine glucose ST:STUDY_SUMMARY present and blood glucose was >288 mg/dl, the animal received a third implant. ST:STUDY_SUMMARY insulin treatment was continued until initially lower plasma glucose content in ST:STUDY_SUMMARY animals reached control values. Three weeks following implantation, diabetic ST:STUDY_SUMMARY were divided randomly into diabetic-treated (D + I; n = 13) and ST:STUDY_SUMMARY (D ? I; n = 13) groups. Insulin implants were removed from the D ? I group ST:STUDY_SUMMARY pentobarbital anesthesia, which led to the return of the diabetic phenotype ST:STUDY_SUMMARY 24 h. Animals from the D + I group continued on insulin treatment (Fig. 1). At ST:STUDY_SUMMARY age of 18 wk, animals from all groups were analyzed for body composition by an ST:STUDY_SUMMARY Body Composition Analyzer (EchoMRI, Houston, TX) and euthanized by decapitation ST:STUDY_SUMMARY wk after the initial STZ or vehicle dose. Figure 1 depicts the timeline of the ST:STUDY_SUMMARY and blood glucose profiles for each experimental group. Additional animals were ST:STUDY_SUMMARY for estimation of skeletal muscle insulin sensitivity by acute insulin ST:STUDY_SUMMARY The mice were divided into the C (n = 6), D ? I (n = 7), and D + I (n = 7) ST:STUDY_SUMMARY and followed appropriate experimental treatment, except for acute insulin ST:STUDY_SUMMARY 10 min prior to euthanization by pentobarbital overdose. Figure 1 of the ST:STUDY_SUMMARY PDF of the article summarizes the study design ST:INSTITUTE Mayo Clinic ST:DEPARTMENT Endocrinology ST:LAST_NAME Nair ST:FIRST_NAME Sreekumaran ST:ADDRESS - ST:EMAIL Dasari.Surendra@mayo.edu ST:PHONE - ST:NUM_GROUPS 3 ST:TOTAL_SUBJECTS 39 #SUBJECT SU:SUBJECT_TYPE Animal SU:SUBJECT_SPECIES Mus musculus SU:TAXONOMY_ID 10090 SU:GENOTYPE_STRAIN C57BL/6J SU:AGE_OR_AGE_RANGE 13-wk-old SU:GENDER Male SU:SPECIES_GROUP Mammal #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - C2 Treatment:control SUBJECT_SAMPLE_FACTORS - C3 Treatment:control SUBJECT_SAMPLE_FACTORS - C35 Treatment:control SUBJECT_SAMPLE_FACTORS - C38 Treatment:control SUBJECT_SAMPLE_FACTORS - C4 Treatment:control SUBJECT_SAMPLE_FACTORS - C44 Treatment:control SUBJECT_SAMPLE_FACTORS - C45 Treatment:control SUBJECT_SAMPLE_FACTORS - C47 Treatment:control SUBJECT_SAMPLE_FACTORS - C48 Treatment:control SUBJECT_SAMPLE_FACTORS - C49 Treatment:control SUBJECT_SAMPLE_FACTORS - C5 Treatment:control SUBJECT_SAMPLE_FACTORS - C50 Treatment:control SUBJECT_SAMPLE_FACTORS - C51 Treatment:control SUBJECT_SAMPLE_FACTORS - C6 Treatment:control SUBJECT_SAMPLE_FACTORS - D+14 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+21 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+23 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+24 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+32 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+52 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+53 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+54 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+55 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+56 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+57 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+58 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D+70 Treatment:diabetic treated SUBJECT_SAMPLE_FACTORS - D-25 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-28 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-31 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-33 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-36 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-39 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-40 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-41 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-42 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-43 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-60 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-61 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-63 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-64 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-67 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-68 Treatment:diabetic untreated SUBJECT_SAMPLE_FACTORS - D-69 Treatment:diabetic untreated #COLLECTION CO:COLLECTION_SUMMARY Mitochondria were isolated from quadriceps muscle by differential CO:COLLECTION_SUMMARY as described previously (38). Briefly, quadriceps muscle samples were CO:COLLECTION_SUMMARY on ice using a motor-driven Potter-Elvehjem tissue grinder. After initial CO:COLLECTION_SUMMARY the supernatant containing the mitochondrial and sarcoplasmic fraction was CO:COLLECTION_SUMMARY to a chilled microcentrifuge tube and centrifuged at 10,000 g for 2 min to CO:COLLECTION_SUMMARY mitochondria. The supernatant containing sarcoplasmic fraction was frozen for CO:COLLECTION_SUMMARY analysis. Mitochondrial pellet was washed twice by resuspending/centrifugation CO:COLLECTION_SUMMARY finally suspended in a mitochondrial storage buffer. The levels of both the CO:COLLECTION_SUMMARY and sphingolipids in homogenates and various muscle fractions were normalized CO:COLLECTION_SUMMARY total protein content, as measured by 660 nm Protein Assay (Thermo Scientific; CO:COLLECTION_SUMMARY Protein Biology Products, Rockford, IL). #TREATMENT TR:TREATMENT_SUMMARY Control/Diabetic; insulin treated/Diabetic; insulin deprived TR:TREATMENT_COMPOUND blank/Insulin/Insulin TR:TREATMENT_ROUTE Skin implants TR:ANIMAL_ANESTHESIA phenobarbital TR:ANIMAL_ENDP_EUTHANASIA 5 weeks after treatment TR:ANIMAL_ENDP_TISSUE_COLL_LIST plasma, muscle, liver and skin #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Mitochondria were isolated from quadriceps muscle by differential SP:SAMPLEPREP_SUMMARY as described previously (38). Briefly, quadriceps muscle samples were SP:SAMPLEPREP_SUMMARY on ice using a motor-driven Potter-Elvehjem tissue grinder. After initial SP:SAMPLEPREP_SUMMARY the supernatant containing the mitochondrial and sarcoplasmic fraction was SP:SAMPLEPREP_SUMMARY to a chilled microcentrifuge tube and centrifuged at 10,000 g for 2 min to SP:SAMPLEPREP_SUMMARY mitochondria. The supernatant containing sarcoplasmic fraction was frozen for SP:SAMPLEPREP_SUMMARY analysis. Mitochondrial pellet was washed twice by resuspending/centrifugation SP:SAMPLEPREP_SUMMARY finally suspended in a mitochondrial storage buffer. The levels of both the SP:SAMPLEPREP_SUMMARY and sphingolipids in homogenates and various muscle fractions were normalized SP:SAMPLEPREP_SUMMARY total protein content, as measured by 660 nm Protein Assay (Thermo Scientific; SP:SAMPLEPREP_SUMMARY Protein Biology Products, Rockford, IL). / Plasma free fatty acid SP:SAMPLEPREP_SUMMARY were measured by liquid chromatography/mass spectrometry (LC/MS), as described SP:SAMPLEPREP_SUMMARY (51). Briefly, 50 ?l of plasma was spiked with heptadecanoate internal standard SP:SAMPLEPREP_SUMMARY and analyzed with Applied Biosystems (Foster City, CA) API5000 mass SP:SAMPLEPREP_SUMMARY coupled with a Cohesive (Franklin, MA) TX2 liquid chromatography system. SP:SAMPLEPREP_SUMMARY of individual FFA was measured against a six-point standard curve prepared for SP:SAMPLEPREP_SUMMARY analyte. Both the ISTD and individual FFA standard curves were prepared in 2% SP:SAMPLEPREP_SUMMARY acid-free human albumin solution. All analytes were monitored as their [M ? H]? SP:SAMPLEPREP_SUMMARY plasma LCFa-CoA esters were estimated using the LC-MS/MS method (9). After SP:SAMPLEPREP_SUMMARY in the presence of internal standard (20 ng of heptadecanoyl-CoA), samples were SP:SAMPLEPREP_SUMMARY by UHPLC-ESI-MS/MS operating in multiple reaction monitoring mode [Waters SP:SAMPLEPREP_SUMMARY UHPLC, C8 UPLC BEH column 2.1 × 150 mm, 1.7 ?m (Waters, Milford, MA) and TSQ SP:SAMPLEPREP_SUMMARY Ultra triple-quad mass spectrometer (Thermo Fisher Scientific, Waltham, MA)]. SP:SAMPLEPREP_SUMMARY standard curves were prepared using chemicals from Avanti Polar Lipids. SP:SAMPLEPREP_PROTOCOL_FILENAME PMID-24368672-Zabielski-Nair-AJPEM-2014.pdf SP:SAMPLEPREP_PROTOCOL_COMMENTS Pubmed ID: 24368672 #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Plasma free fatty acid concentrations were measured by liquid CH:CHROMATOGRAPHY_SUMMARY spectrometry (LC/MS), as described previously (51). Briefly, 50 ?l of plasma CH:CHROMATOGRAPHY_SUMMARY spiked with heptadecanoate internal standard (ISTD) and analyzed with Applied CH:CHROMATOGRAPHY_SUMMARY (Foster City, CA) API5000 mass spectrometer coupled with a Cohesive (Franklin, CH:CHROMATOGRAPHY_SUMMARY TX2 liquid chromatography system. Concentration of individual FFA was measured CH:CHROMATOGRAPHY_SUMMARY a six-point standard curve prepared for each analyte. Both the ISTD and CH:CHROMATOGRAPHY_SUMMARY FFA standard curves were prepared in 2% fatty acid-free human albumin solution. CH:CHROMATOGRAPHY_SUMMARY analytes were monitored as their [M ? H]? ions. LCFa-CoA esters were estimated CH:CHROMATOGRAPHY_SUMMARY the LC-MS/MS method (9). After extraction in the presence of internal standard CH:CHROMATOGRAPHY_SUMMARY ng of heptadecanoyl-CoA), samples were analyzed by UHPLC-ESI-MS/MS operating in CH:CHROMATOGRAPHY_SUMMARY reaction monitoring mode [Waters Acquity UHPLC, C8 UPLC BEH column 2.1 150 mm, CH:CHROMATOGRAPHY_SUMMARY ?m (Waters, Milford, MA) and TSQ Quantum Ultra triple-quad mass spectrometer CH:CHROMATOGRAPHY_SUMMARY Fisher Scientific, Waltham, MA)]. All standard curves were prepared using CH:CHROMATOGRAPHY_SUMMARY from Avanti Polar Lipids. CH:CHROMATOGRAPHY_TYPE - CH:INSTRUMENT_NAME - CH:COLUMN_NAME - CH:METHODS_FILENAME PMID-24368672-Zabielski-Nair-AJPEM-2014.pdf CH:CHROMATOGRAPHY_COMMENTS Pubmed ID: 24368672 #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME Thermo TSQ Quantum Ultra MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:MS_COMMENTS LCFa-CoA esters were estimated using the LC-MS/MS method (9). After extraction MS:MS_COMMENTS the presence of internal standard (20 ng of heptadecanoyl-CoA), samples were MS:MS_COMMENTS by UHPLC-ESI-MS/MS operating in multiple reaction monitoring mode [Waters MS:MS_COMMENTS UHPLC, C8 UPLC BEH column 2.1 × 150 mm, 1.7 um (Waters, Milford, MA) and TSQ MS:MS_COMMENTS Ultra triple-quad mass spectrometer (Thermo Fisher Scientific, Waltham, MA)]. MS:MS_COMMENTS standard curves were prepared using chemicals from Avanti Polar Lipids. MS:MS_COMMENTS UHPLC-ESI-MS/MS operating in multiple reaction monitoring mode [Waters Acquity MS:MS_COMMENTS C8 UPLC BEH column 2.1 × 150 mm, 1.7 ?m (Waters, Milford, MA) and TSQ Quantum MS:MS_COMMENTS triple-quad mass spectrometer (Thermo Fisher Scientific, Waltham, MA)]. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS uM MS_METABOLITE_DATA_START Samples C2 C35 C38 C4 C44 C45 C47 C48 C5 C51 C6 D+14 D+21 D+23 D+24 D+32 D+52 D+53 D+54 D+55 D+56 D+57 D+58 D+70 D-33 D-36 D-39 D-40 D-41 D-42 D-43 D-60 D-63 D-64 D-67 D-68 D-69 Factors Treatment:control Treatment:control Treatment:control Treatment:control Treatment:control Treatment:control Treatment:control Treatment:control Treatment:control Treatment:control Treatment:control Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic treated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated Treatment:diabetic untreated CoA(C14:0) 5.2848 6.2778 4.9347 6.3311 5.2943 4.8208 4.7555 4.9267 5.0689 5.9069 4.8734 5.0065 7.7689 5.6185 4.7954 4.7573 4.8604 5.1954 6.5832 5.1038 6.1258 5.0516 5.0680 4.7984 11.6771 7.9040 10.5392 9.1245 11.8395 7.2200 6.1279 7.9160 7.1086 16.7366 7.0848 9.9473 8.3607 CoA(C16:0) 23.9899 23.1492 22.7642 29.8621 25.9300 21.6483 26.0008 21.6630 27.7154 22.3276 19.6078 22.6803 23.5973 24.3506 20.3009 19.8533 22.7783 22.7070 24.5314 28.3529 29.9417 29.9987 21.8870 29.0076 36.6983 33.8463 42.9457 47.7846 42.5615 35.7478 26.5678 35.8500 42.5596 47.1494 25.4268 27.5228 34.3775 CoA(C16:1) 6.8233 6.2519 5.0813 6.9984 4.5096 5.2159 5.3040 5.0678 6.6766 4.8775 5.3869 6.0882 8.9806 7.6869 6.9152 5.0316 5.3544 5.5338 5.2039 6.3070 5.2433 5.2229 5.1413 4.9179 16.1202 10.6829 14.2667 10.0275 12.1121 15.4596 15.4456 15.2491 12.9316 11.3667 15.3407 13.7176 10.7117 CoA(C18:0) 16.4007 15.1143 19.6168 18.9009 16.8359 19.3660 16.0700 17.7580 18.7419 16.5090 15.5846 26.1486 18.7576 23.6485 22.5114 26.4127 19.1982 24.8529 27.5744 21.9703 20.7842 24.1803 23.1946 17.0495 35.0515 34.1142 39.1733 36.2577 27.7970 33.9040 33.4642 29.4441 39.8497 27.5128 31.5765 34.3647 35.0375 CoA(C18:1) 127.0393 150.4921 153.8324 122.1919 153.5189 140.3683 196.1930 140.6318 199.5369 190.3457 135.5862 153.1214 238.6221 195.4221 243.4459 248.0229 250.1856 279.1965 267.2188 225.8604 315.1545 199.7275 211.2388 244.8166 339.4013 365.4142 397.6767 348.1690 316.9819 317.8112 397.5645 303.3289 382.1000 330.7714 300.7500 331.9967 369.8437 CoA(C18:2) 23.8905 18.5148 20.9020 24.6729 20.1013 18.3353 20.9066 19.6199 23.1227 23.6154 21.2328 26.4506 25.0762 24.6886 26.1773 27.5672 26.7162 24.8892 21.3818 22.8363 23.8613 28.8370 23.2404 26.9156 38.5613 36.8439 36.4021 30.8827 38.4368 32.4936 27.6908 29.5947 34.6330 29.0255 29.5366 31.5836 35.8978 CoA(C20:0) 8.3788 9.2092 8.9167 9.8753 7.6880 9.2592 8.4641 9.3432 7.0205 8.4396 8.0056 8.3038 9.4741 7.6048 7.5877 10.2779 8.8250 11.0171 8.9912 9.8948 10.9749 10.2920 9.1123 11.8782 12.1054 13.4570 15.2562 9.5571 10.4248 15.2788 9.5028 9.1944 19.7083 12.5794 15.4695 12.3302 13.1275 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name moverz_quant ri ri_type pubchem_id inchi_key kegg_id other_id other_id_type CoA(C14:0) MAYO_ID CoA(C16:0) MAYO_ID CoA(C16:1) MAYO_ID CoA(C18:0) MAYO_ID CoA(C18:1) MAYO_ID CoA(C18:2) MAYO_ID CoA(C20:0) MAYO_ID METABOLITES_END #END